Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis.

J Hematol Oncol · 2025 · PMC11881499 · PMID 40038780

Europe PMC DOI

hedged sentences

0.0610

closest p · 1.2× alpha

0.1400

boldest claim

The sentences

showed a trendP = 0.061so close (0.05 < p ≤ 0.1)

Moreover, RT plus YM101 exhibited enhanced antitumor activity relative to RT plus αTGF-β ( P = 0.0318), and showed a trend toward improvement compared with RT plus αPD-L1 ( P = 0.061).

also in 53,322 other papers

a trend towards significanceP = 0.14not close (p > 0.1)

Furthermore, in the 4T1 model, RT plus YM101 significantly improved survival compared with RT plus αTGF-β ( P = 0.02), while showing a trend towards significance compared with RT plus αPD-L1 ( P = 0.14).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.